Page last updated: 2024-09-05

cilengitide and Adenocarcinoma

cilengitide has been researched along with Adenocarcinoma in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Oron, Y	1
Atanackovic, D; Barlesi, F; Bennouna, J; Feurer, M; Germonpre, P; Goekkurt, E; Gridelli, C; Hicking, C; Krzakowski, M; Lena, H; Milanowski, J; O'Byrne, K; Picard, M; Schuette, W; Straub, J; Szczesna, A; Vansteenkiste, J; Verhoeven, D; Waller, CF	1
Burke, PA; DeNardo, GL; DeNardo, SJ; Lamborn, KR; Matzku, S; Miers, LA	1

Reviews

1 review(s) available for cilengitide and Adenocarcinoma

Article	Year
Integrin-based therapy of pancreatic adenocarcinoma: current status and future perspectives. Minerva gastroenterologica e dietologica, 2015, Volume: 61, Issue:2 Topics: Adenocarcinoma; Clinical Trials as Topic; Forecasting; Humans; Integrins; Pancreatic Neoplasms; Snake Venoms	2015

Trials

1 trial(s) available for cilengitide and Adenocarcinoma

Article	Year
Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO). Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Integrin alphaVbeta3; Lung Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Receptors, Vitronectin; Snake Venoms; Treatment Outcome; Vinblastine; Vinorelbine	2015

Article

Year

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).

Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:8

Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Integrin alphaVbeta3; Lung Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Receptors, Vitronectin; Snake Venoms; Treatment Outcome; Vinblastine; Vinorelbine

2015

Other Studies

1 other study(ies) available for cilengitide and Adenocarcinoma

Article	Year
Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer research, 2002, Aug-01, Volume: 62, Issue:15 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Apoptosis; Breast Neoplasms; Cell Division; Combined Modality Therapy; Endothelium, Vascular; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Radioimmunotherapy; Receptors, Vitronectin; Snake Venoms; Xenograft Model Antitumor Assays	2002

Article

Year

Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.

Cancer research, 2002, Aug-01, Volume: 62, Issue:15

Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Apoptosis; Breast Neoplasms; Cell Division; Combined Modality Therapy; Endothelium, Vascular; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Radioimmunotherapy; Receptors, Vitronectin; Snake Venoms; Xenograft Model Antitumor Assays

2002